A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, Pharmacokinetic/Pharmacodynamic, and Preliminary Efficacy Study of Subcutaneous Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C

The primary objective of this study is to evaluate the safety and tolerability of ascending doses of Hanferon™ in combination with ribavirin (RBV). The secondary objective of this study is to define the PK and PD of ascending doses of Hanferon™ in combination with RBV. The exploratory objective of this study is to make a preliminary assessment of Hanferon™ efficacy in combination with RBV.

开始日期2011-06-01

申办/合作机构

HANALL BIOPHARMA Co., Ltd.

EUCTR2008-006208-52-DE / Not yet recruitingN/A

Mono-centre, open-label study to investigate the multi-dose pharmacokinetics, efficacy and safety of Interferon alpha-2b Cream in women with a history of cytological diagnosed Pap IIID, with a confirmed histological diagnosis of CIN I or II, and of confirmed HPV+ status - Interferon alpha-2b kinetics in Pap IIID women

开始日期2009-03-09

申办/合作机构

Helix BioPharma Corp.

100 项与 Interferon alfa-2b(Nautilus Biotech SA) 相关的临床结果

登录后查看更多信息

100 项与 Interferon alfa-2b(Nautilus Biotech SA) 相关的转化医学

登录后查看更多信息

100 项与 Interferon alfa-2b(Nautilus Biotech SA) 相关的专利（医药）

登录后查看更多信息

项与 Interferon alfa-2b(Nautilus Biotech SA) 相关的文献（医药）

2020-12-01·Zhongguo shi yan xue ye xue za zhi

[Effect of 5-aminoimidazole-4-formamide Ribonucleotide Combined with Interferon on Chronic Myeloid Leukemia K562 Cells].

Article

作者: Liu, Rui ; Zhang, Yuan-Yuan ; Wang, Hong-Juan ; Ge, Fan-Mei

题目5-氨基咪唑-4-甲酰胺核糖核苷酸联合干扰素对K562细胞的影响.目的研究5-氨基咪唑-4-甲酰胺核糖核苷酸（AICAR）联合干扰素（IFN-ɑ-2b）对慢性粒细胞白血病K562细胞的增殖及凋亡的影响，并探讨其可能的作用机制.方法采用CCK-8法检测细胞增殖抑制情况；Wright-Giemsa方法染色，光学显微镜下观察细胞形态；FITC AnnexinV/PI双染法分析细胞凋亡率的变化；免疫细胞化学法检测野生型P53蛋白的阳性表达率.结果不同浓度AICAR于不同作用时间24、48和72 h对K562细胞均有抑制作用，抑制程度呈时间、剂量依赖性（r=0.71，r=0.84）。AICAR与IFN-ɑ-2b联合应用后可以有效抑制K562细胞增殖，促进细胞凋亡，联合作用72 h时细胞的抑制率可达（45.26±2.54）％，联合作用48 h早期凋亡率达（33.72±0.23）％，与对照组及单用AICAR和单用IFN-ɑ-2b相比，差异均有统计学意义（P<0.05）。AICAR与IFN-ɑ-2b联合作用促进野生型P53蛋白的表达.结论AICAR和（或）IFN-ɑ-2b能抑制细胞增殖，促进K562细胞凋亡，2药联合具有协同抗瘤效应，其作用机制可能与促进野生型P53蛋白高表达有关.

2015-09-01·Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

[Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection].

Article

作者: Zhang, Shu ; Liu, Layang ; Jia, Xiaoli ; Li, Zongfang ; Cai, Zhifang ; Xue, Hong-an ; Huang, Na ; Dang, Shuangsuo ; Wang, Yuan ; Guo, Yonghong ; Ji, Fanpu ; Deng, Hong

OBJECTIVETo investigate the efficacy and safety of antiviral treatment in patients with hepatitis C virus (HCV) infection and decompensated cirrhosis and determine the effects of virological response on long-term prognosis.METHODSSixty-six consecutive,interferon (IFN)-na(i)ve patients with HCV infection and decompensated cirrhosis were enrolled in this prospective study. All patients were given a 48-to 72-week course of IFN plus ribavirin (RBV) combined therapy,with a low accelerating dosage regimen using either:pegylated (PEG)-IFNa-2b at 1.0-1.5 mug/kg/week,PEG-IFNa-2a at 90-180 mug,or standard IFN-a-2b at 3MU,every other day.RBV was given at 800 to 1000 mg/day. All patients were routinely monitored for adverse drug reactions and virological response.Effects of treatments on patient survival were assessed by Kaplan-Meier analysis.RESULTSAt the end of treatment,74.2% of patients were HCV RNA-negative,with 45.5% having achieved sustained virological response and 28.8% having relapsed;the remaining 25.7% of patients showed non-virological response (NVR). Among the patients with HCV genotype 1, 65.9% achieved end-of-treatment virological response (ETVR) and 34.1% achieved SVR;among the patients with HCV genotype 2,90.9% achieved ETVR and 68.2% achieved SVR. The positive and negative predictive values of early virological response (EVR) for ETVR were 95.7% and 75.0% respectively, and for SVR were 65.2% and 100% respectively. Compared with baseline,patients who achieved ETVR had better liver function,as evidenced by changes in levels of total bilirubin,alanine aminotransferase and albumin,as well as prothrombin activity and Child-Pugh score (t =4.564,11.486,2.303,2.699,3.694 respectively, all P less than 0.05).Compared with the NVR patients, the ETVR patients had lower risk of hepatic decompensation and hepatocellular carcinoma, and had improved survival (x2=18.756,6.992,7.580, respectively, all P less than 0.05).Twelve (18.2%) patients experienced serious adverse events,with 10 requiring premature treatment withdrawal and 2 dying.CONCLUSIONAntiviral treatment for patients with HCV infection and decompensated cirrhosis using interferon in a low accelerating dosage regimen in combination with ribavirin is feasible.Patients who achieved ETVR had significantly improved long-term prognosis.

2014-08-01·Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

[Effects of hepatitis C virus core protein on activity of double-stranded RNA-dependent protein kinase].

Article

作者: Dan Zhang ; Guohe Feng

OBJECTIVETo explore the effects of hepatitis C virus (HCV) core protein on the activity of double-stranded RNA-dependent protein kinase (PKR).METHODSThe human hepatoma cell line BEL-7402 was transfected with the HCV core gene-containing eukaryotic expression vector pCMH6K-Core (at various concentrations), or empty vector, or no vector; a group of cells was co-transfected with the luciferase reporter plasmid pGL3-promoter. The cells were treated with interferon (IFN) a-2b to induce the expression and activation of endogenous PKR, or left untreated to serve as controls. The effect of core protein on PKR phosphorylation was detected by western blotting. Luciferase activity was detected to reflect effects of the core protein on the synthesis of cellular proteins. The t-test and F test were used for statistical analyses.RESULTSIn the case of IFNa stimulation, PKR phosphorylation levels were significantly lower in the HCV core protein expressing cells than in the cells transfected with empty plasmid or with no vector, but the total PKR expression level was not significantly different among these three groups of cells. Cells co-transfected with luciferase plasmid and the core protein expressing vector showed significantly higher levels of luciferase expression than the cells co-transfected with the empty vector. Moreover, the luciferase activity and core protein expression levels increased in a dose-dependent manner, with the luciferase activity of the cells treated with 0.5 mug, 1.0 mug and 1.5 mug pCMH6K-Core being 1.941 ± 0.199 times, 2.868 ± 0.275 times and 3.839 ± 0.338 times higher than that of the empty vector group (all P < 0.05).CONCLUSIONIn the human hepatoma cell line BEL-7402, the HCV core protein can inhibit the activity of endogenous PKR, thereby promoting cell protein synthesis.

项与 Interferon alfa-2b(Nautilus Biotech SA) 相关的新闻（医药）

2023-09-05

·GlobeNewswire-Health Care

CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in September. H.C. Wainwright 25th Annual Global Investment Conference Date: Tuesday, September 12, 2023 Company Presentation: 11:30 a.m. ET Location: New York, NY Cantor Global Healthcare Conference Date: Tuesday, September 26, 2023 Fireside Chat: 8:10 a.m. ET Location: New York, NY Live webcasts of the H.C. Wainwright presentation and Cantor fireside chat will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences. About CytomX TherapeuticsCytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engaging bispecific antibodies, and immune modulators such as cytokines and checkpoint inhibitors. CX-904 is a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells, which is partnered with Amgen. CytomX’s clinical pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutic BMS-986288, partnered with Bristol Myers Squibb. In addition, CytomX has a diverse preclinical portfolio of wholly-owned assets including CX-2051, a conditionally activated ADC directed toward EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers, and CX-801, an interferon alpha-2b Probody cytokine that has broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has also established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and Twitter. Probody is a U.S. registered trademark of CytomX Therapeutics, Inc. CytomX Contact:Chris OgdenSVP, Finance and Accounting cogden@cytomx.com (317) 767-4764 Investor and Media Contact:Stern Investor RelationsStephanie Ascherstephanie.ascher@sternir.com212-362-1200

免疫疗法抗体药物偶联物

2023-09-05

·BioSpace

CytomX Therapeutics to Present at Upcoming September 2023 Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in September. H.C. Wainwright 25th Annual Global Investment Conference Date: Tuesday, September 12, 2023 Company Presentation: 11:30 a.m. ET Location: New York, NY Cantor Global Healthcare Conference Date: Tuesday, September 26, 2023 Fireside Chat: 8:10 a.m. ET Location: New York, NY Live webcasts of the H.C. Wainwright presentation and Cantor fireside chat will be available on the Events and Presentations page of CytomX’s website at . In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences. About CytomX Therapeutics CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engaging bispecific antibodies, and immune modulators such as cytokines and checkpoint inhibitors. CX-904 is a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells, which is partnered with Amgen. CytomX’s clinical pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutic BMS-986288, partnered with Bristol Myers Squibb. In addition, CytomX has a diverse preclinical portfolio of wholly-owned assets including CX-2051, a conditionally activated ADC directed toward EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers, and CX-801, an interferon alpha-2b Probody cytokine that has broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has also established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit and follow us on LinkedIn and Twitter. Probody is a U.S. registered trademark of CytomX Therapeutics, Inc. CytomX Contact: Chris Ogden SVP, Finance and Accounting cogden@cytomx.com (317) 767-4764 Investor and Media Contact: Stern Investor Relations Stephanie Ascher stephanie.ascher@sternir.com 212-362-1200

免疫疗法抗体药物偶联物

2023-08-10

·BioSpace

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the H.C. Wainwright Immune Cell Engager Virtual Conference on Thursday, August 17 at 9:00 a.m. ET. A live webcast of the fireside chat will be available on the Events and Presentations page of CytomX’s website at . In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences. About CytomX Therapeutics CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics localized to the tumor microenvironment. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engaging bispecific antibodies, and immune modulators such as cytokines and checkpoint inhibitors. CX-2029 is an investigational conditionally ADCs directed toward CD71. CytomX’s clinical pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutic BMS-986288, partnered with Bristol Myers Squibb, as well as CX-904, a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells, which is partnered with Amgen. In addition, CytomX has a diverse preclinical portfolio of wholly-owned assets including CX-801, an interferon alpha-2b Probody cytokine that has broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors and CX-2051, a conditionally activated ADC directed toward EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CytomX has also established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit and follow us on LinkedIn and Twitter. Probody is a U.S. registered trademark of CytomX Therapeutics, Inc. CytomX Contact: Chris Ogden SVP, Finance and Accounting cogden@cytomx.com (317) 767-4764 Investor and Media Contact: Stern Investor Relations Stephanie Ascher stephanie.ascher@sternir.com 212-362-1200

免疫疗法抗体药物偶联物

100 项与 Interferon alfa-2b(Nautilus Biotech SA) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Interferon alfa-2b(Nautilus Biotech SA)	-	DB00105

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性丙型肝炎	临床3期	美国	HANALL BIOPHARMA Co., Ltd.	2011-06-01
丙型肝炎	临床2期	-	HANALL BIOPHARMA Co., Ltd.	-
肝细胞癌	临床2期	-	HANALL BIOPHARMA Co., Ltd.	-
慢性丙型肝炎基因型 1	临床前	美国	HANALL BIOPHARMA Co., Ltd.	2011-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


IAS2002	N/A	HIV感染 \| 丙型肝炎	47	IFN-alpha-2b/RBV	網構願餘淵醖壓觸襯衊(壓鏇壓憲淵範獵夢襯選) = 淵鏇醖壓鬱鏇願醖積窪觸夢願淵淵範衊鏇繭衊 (齋製壓簾鹹顧艱鑰遞遞 ) 更多	-	2002-01-01
				pegIFN-alpha-2b/RBV	網構願餘淵醖壓觸襯衊(壓鏇壓憲淵範獵夢襯選) = 積繭衊蓋遞簾範鹹壓醖觸夢願淵淵範衊鏇繭衊 (齋製壓簾鹹顧艱鑰遞遞 ) 更多